Related Experiment Video
Updated: Aug 9, 2026

Atomic Scale Structural Studies of Macromolecular Assemblies by Solid-state Nuclear Magnetic Resonance Spectroscopy
Published on: September 17, 2017
Self-assembly of beta-amyloid 42 is retarded by small molecular ligands at the stage of structural intermediates
B Bohrmann1, M Adrian, J Dubochet
1Pharma Division, F. Hoffmann-La Roche AG, Basel, CH-4070, Switzerland. bernd.bohrmann@roche.com
Abstract:
Assemblyof the amyloid-beta peptide (Abeta) into fibrils and its deposition in distinct brain areas is considered responsible for the pathogenesis of Alzheimer's disease (AD). Thus, inhibition of fibril assembly is a potential strategy for therapeutic intervention. Electron cryomicroscopy was used to monitor the initial, native assembly structure of Abeta42. In addition to the known fibrillar intermediates, a nonfibrillar, polymeric sheet-like structure was identified. A temporary sequence of supramolecular structures was revealed with (i) polymeric Abeta42 sheets during the onset of assembly, inversely related to the appearance of (ii) fibril intermediates, which again are time-dependently replaced by (iii) mature fibrils. A cell-based primary screening assay was used to identify compounds that decrease Abeta42-induced toxicity. Hit compounds were further assayed for binding to Abeta42, radical scavenger activity, and their influence on the assembly structure of Abeta42. One compound, Ro 90-7501, was found to efficiently retard mature fibril formation, while extended polymeric Abeta42 sheets and fibrillar intermediates are accumulated. Ro 90-7501 may serve as a prototypic inhibitor for Abeta42 fibril formation and as a tool for studying the molecular mechanism of fibril assembly.
Insights
Researchers identified a novel polymeric sheet structure during amyloid-beta (Abeta) assembly, a key process in Alzheimer's disease (AD). A compound, Ro 90-7501, was found to inhibit Abeta fibril formation, offering a potential therapeutic strategy for AD.
Area of Science:
- Biochemistry
- Neuroscience
- Structural Biology
Background:
- Alzheimer's disease (AD) pathogenesis is linked to amyloid-beta (Abeta) peptide aggregation into fibrils.
- Inhibiting Abeta fibril assembly presents a promising therapeutic avenue for AD.
Purpose of the Study:
- To investigate the initial native assembly structure of Abeta42 using electron cryomicroscopy.
- To identify compounds that reduce Abeta42-induced toxicity and inhibit fibril formation.
Main Methods:
- Electron cryomicroscopy to visualize Abeta42 assembly intermediates.
- Cell-based screening assay to identify toxicity-reducing compounds.
- Assays for compound binding, radical scavenging, and influence on Abeta42 assembly.
Main Results:
- A nonfibrillar, polymeric Abeta42 sheet structure was identified alongside known fibrillar intermediates.
- A temporal sequence of assembly was observed: sheets, then intermediates, then mature fibrils.
- Compound Ro 90-7501 inhibited mature fibril formation, accumulating earlier structures.
Conclusions:
- Abeta assembly involves a transient polymeric sheet intermediate.
- Ro 90-7501 acts as a prototypic inhibitor of Abeta42 fibril formation.
- This compound can be a tool for studying the molecular mechanisms of Abeta assembly.
Related Concept Videos
Protein Folding
Protein Complex Assembly
Many viruses self-assemble into a fully functional unit using the infected host cell to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Oligosaccharide Assembly
Multiple sugar molecules that may or may...
Protein Folding
Protein Structure Is Critical to Its Biological Function
Proteins perform a wide range of biological functions such as catalyzing chemical reactions, providing...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...

